244 related articles for article (PubMed ID: 28632422)
1. Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland.
Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
Nord J Psychiatry; 2017 Oct; 71(7):496-502. PubMed ID: 28632422
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland.
Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
BMC Psychiatry; 2016 Dec; 16(1):441. PubMed ID: 27955666
[TBL] [Abstract][Full Text] [Related]
3. Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records.
Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
Nord J Psychiatry; 2016 Aug; 70(6):450-5. PubMed ID: 27049594
[TBL] [Abstract][Full Text] [Related]
4. Constipation, ileus and medication use during clozapine treatment in patients with schizophrenia in Iceland.
Ingimarsson O; MacCabe JH; Sigurdsson E
Nord J Psychiatry; 2018 Oct; 72(7):497-500. PubMed ID: 30348045
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
6. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
7. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia.
Schulte PF; Bocxe JT; Doodeman HJ; van Haelst IM; Cohen D
J Clin Psychopharmacol; 2016 Apr; 36(2):115-9. PubMed ID: 26872114
[TBL] [Abstract][Full Text] [Related]
8. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
Lund BC; Perry PJ; Brooks JM; Arndt S
Arch Gen Psychiatry; 2001 Dec; 58(12):1172-6. PubMed ID: 11735847
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
[TBL] [Abstract][Full Text] [Related]
10. [Schizophrenia and diabetes mellitus: not an improbable combination].
Cohen D; Gispen-de Wied CC
Ned Tijdschr Geneeskd; 2003 May; 147(21):993-6. PubMed ID: 12811967
[TBL] [Abstract][Full Text] [Related]
11. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.
Lamberti JS; Costea GO; Olson D; Crilly JF; Maharaj K; Tu X; Groman A; Dietz MB; Bushey MP; Olivares T; Wiener K
J Clin Psychiatry; 2005 Jul; 66(7):900-6. PubMed ID: 16013906
[TBL] [Abstract][Full Text] [Related]
12. Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.
Xiong Z; Cheng M; Zhu P; Huang S; Guo J; Zhang W; Zhou H; Shu Y; Li Q
Hum Psychopharmacol; 2019 Jul; 34(4):e2699. PubMed ID: 31273857
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.
Hägg S; Joelsson L; Mjörndal T; Spigset O; Oja G; Dahlqvist R
J Clin Psychiatry; 1998 Jun; 59(6):294-9. PubMed ID: 9671341
[TBL] [Abstract][Full Text] [Related]
14. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
[TBL] [Abstract][Full Text] [Related]
15. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics.
Leitão-Azevedo CL; Guimarães LR; de Abreu MG; Gama CS; Lobato MI; Belmonte-de-Abreu PS
Braz J Psychiatry; 2006 Dec; 28(4):301-4. PubMed ID: 17242810
[TBL] [Abstract][Full Text] [Related]
16. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
17. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
18. What evidence is there to show which antipsychotics are more diabetogenic than others?
Jesus C; Jesus I; Agius M
Psychiatr Danub; 2015 Sep; 27 Suppl 1():S423-8. PubMed ID: 26417808
[TBL] [Abstract][Full Text] [Related]
19. Factors in antipsychotic drug selection: tolerability considerations.
Nasrallah HA
CNS Spectr; 2003 Nov; 8(11 Suppl 2):23-5. PubMed ID: 14978455
[TBL] [Abstract][Full Text] [Related]
20. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
